Short-term Efficacy Of Endostar Combined With Chemotherapy In Treating Advanced Lung Cancer

Objective: The incidence and mortality of lung cancer is the highest malignant tumor in the word,and chemotherapy plays a leading role in the systemic treatment of lung cancer,But traditional chemotherapy regimens containing platinum have limited curative effect,recombinant human endostatin(Endostar)plays an important role in the inhibition of tumor occurrence,development,invasion and metastasis.in patients with lung cancer,The vascular endothelial growth factor(VEGF)and carcinoembryonic antigen(CEA)in lung cancer patients have certain expression,this paper mainly study of Endostar combined with chemotherapy in treatment of advanced lung cancer,and discuss weather VEGF and CEA can be used as indicators of therapeutic efficacy evaluation.Methods: The patient was admitted to respiratory department of yijshan hospital form October 2015 to October 2018 and confirmed as lung malignancy by pathology.The experimental group was treated Endostar combined with chemotherapy,the control group were randomly selected and treated with platinum containing two drug regimen.To evaluate the efficacy and adverse reaction of two kinds of chemotherapy after 2cycles according to Response Evaluation Criteria in Solid Tumors.Before and after 2cycles of chemotherapy,use Enzyme-linked immunosorbent assay to detect VEGF and CEA concentration.Results: All 38 patients in the chemotherapy group and Endostar combined with chemotherapy group has completed 2 cycles of chemotherapy.The complete response of the combined chemotherapy group is 0,partial response is 10 cases,progressivedisease is 25 cases,progressive disease is 3cases,the objective response rate is26.3%,disease control rate is 92.3%.The complete response of chemotherapy group is0,partial response is7 cases,progressive disease is 16 cases,progressive disease is15 cases,the objective response rate is 18.4%,disease control rate is 60.5%.Comparing the objective response rate of two groups,P>0.05,the difference have no statistical significance.Comparing the disease control rate of two groups,P<0.05,the difference have statistical significance.The effect of clinical features on the recent efficacy of Endostar combined with chemotherapy,there is no statistical significance in non-small cell lung cancer and small cell lung cancer of ORR and DCR(P>0.05),there is no statistical significance in male and female of ORR and DCR(P>0.05),there is no statistical significance in age >60 years and less than 60 years of ORR and DCR(P>0.05),there is no statistical significance in smoking and non-smoking of ORR and DCR(P>0.05),there is no significant difference in the concentration of CEA and VEGF between the chemotherapy group and the combined chemotherapy group before chemotherapy(P>0.05).Comparing the chemotherapy group and the combined chemotherapy group after 2 cycles of chemotherapy,CEA decrease obviously(P<0.05)and VEGF decrease not obviously(P>0.05),Both CEA and VEGF in the chemotherapy group and Endostar combined with chemotherapy group is significantly decreas(P<0.001).Before chemotherapy,CEA is positively correlate with VEGF in Endostar combined with chemotherapy group(r=0.808,P<0.001).After 2 cycles of chemotherapy,VEGF and CEA is positively correlate in Endostar combined with chemotherapy group(r=0.569,P<0.001).Before chemotherapy,CEA is positively correlate with VEGF in chemotherapy group(r=0.678,P<0.001).After 2 cycles of chemotherapy,CEA is positively correlate with VEGF in chemotherapy group(r=0.701,P<0.001).Compering chemotherapy group and Endostar combined with chemotherapy group,there is no significant difference in heart damage,bone marrow suppression,digestive system reaction,skin allergy,liver damage and renal injury(P>0.05).1.Conclusion: 1.Endostar combined with chemotherapy can improve the disease control rate of patients with lung cancer;2.The recent efficacy of Endostar combined with chemotherapy is not relate to the patient's pathological type(small cell lung small cell lung cancer),age,gender,smoking;3.After 2 cycles of chemotherapy,both CEA and VEGF concentration in chemotherapy group and Endostar combined with chemotherapy group are decrease in different degrees,The decrease of CEA is more obvious in the Endostar combined with chemotherapy group.4.Both VEGF and CEA's concentration is positively correlate before and after chemotherapy.5.Endostar combined with chemotherapy does not increase the frequency and extent of adverse reaction.